EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 183 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $18,761,000 | -49.1% | 449,479 | -43.2% | 0.57% | -25.6% |
| Q4 2020 | $36,865,000 | +36.3% | 791,600 | +24.4% | 0.76% | -27.1% |
| Q3 2020 | $27,040,000 | -49.7% | 636,538 | -43.2% | 1.05% | -60.7% |
| Q2 2020 | $53,749,000 | -5.4% | 1,120,235 | -9.3% | 2.66% | -30.9% |
| Q1 2020 | $56,803,000 | -19.3% | 1,234,856 | +5.4% | 3.86% | +30.1% |
| Q4 2019 | $70,406,000 | +13.8% | 1,171,880 | +7.2% | 2.96% | -1.6% |
| Q3 2019 | $61,848,000 | -14.6% | 1,093,299 | -15.9% | 3.01% | +0.2% |
| Q2 2019 | $72,384,000 | +37.2% | 1,300,000 | +24.4% | 3.01% | +29.9% |
| Q1 2019 | $52,777,000 | +24.8% | 1,045,311 | -0.4% | 2.32% | +10.8% |
| Q4 2018 | $42,304,000 | -17.7% | 1,050,000 | +41.6% | 2.09% | +11.6% |
| Q3 2018 | $51,403,000 | -38.4% | 741,426 | -32.8% | 1.87% | -39.8% |
| Q2 2018 | $83,495,000 | +50.7% | 1,103,556 | +5.0% | 3.11% | +26.1% |
| Q1 2018 | $55,392,000 | +0.1% | 1,051,274 | +1.4% | 2.47% | -2.2% |
| Q4 2017 | $55,358,000 | +2.2% | 1,036,274 | +14.1% | 2.52% | -21.9% |
| Q3 2017 | $54,166,000 | +68.8% | 908,220 | +123.3% | 3.23% | +81.7% |
| Q2 2017 | $32,082,000 | -20.8% | 406,663 | -16.7% | 1.78% | -24.7% |
| Q1 2017 | $40,485,000 | -12.0% | 488,128 | -15.8% | 2.36% | -33.7% |
| Q4 2016 | $45,998,000 | +4.3% | 579,753 | -7.9% | 3.56% | -11.3% |
| Q3 2016 | $44,083,000 | +80.5% | 629,753 | 0.0% | 4.01% | +62.4% |
| Q2 2016 | $24,428,000 | -59.0% | 629,753 | -57.2% | 2.47% | -56.0% |
| Q1 2016 | $59,624,000 | -2.5% | 1,472,197 | +113.4% | 5.61% | -15.0% |
| Q4 2015 | $61,182,000 | +65.1% | 690,000 | +37.8% | 6.60% | +95.5% |
| Q3 2015 | $37,059,000 | -9.0% | 500,591 | -0.6% | 3.38% | -10.7% |
| Q2 2015 | $40,720,000 | +55.6% | 503,585 | -19.4% | 3.78% | -0.8% |
| Q1 2015 | $26,178,000 | +111.1% | 624,920 | -21.9% | 3.82% | +94.1% |
| Q4 2014 | $12,400,000 | +46.9% | 800,000 | +19.9% | 1.97% | +57.5% |
| Q3 2014 | $8,443,000 | +38.0% | 667,462 | +56.4% | 1.25% | +56.4% |
| Q2 2014 | $6,117,000 | +129.4% | 426,900 | +104.1% | 0.80% | +163.4% |
| Q1 2014 | $2,667,000 | – | 209,200 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |